Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer

Trial Profile

A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary) ; Capecitabine
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 02 Jul 2019 The trial is discontinued at UK (End Date: 24 Jan 2017), as per European Clinical Trials Database record.
    • 10 Jul 2017 Status changed from active, no longer recruiting to discontinued as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation
    • 03 Feb 2017 This trial has been completed in Spain (end date: 24 Jan 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top